BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26365710)

  • 1. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
    Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
    Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.
    Sun B; Song S; Hao CZ; Huang WX; Liu CC; Xie HL; Lin B; Cheng MS; Zhao DM
    J Mol Graph Model; 2015 Mar; 56():10-9. PubMed ID: 25541526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1).
    Zhao D; Sun B; Ren J; Li F; Song S; Lv X; Hao C; Cheng M
    Bioorg Med Chem; 2015 Mar; 23(6):1356-65. PubMed ID: 25684424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
    Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).
    Gomaa MS; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    J Med Chem; 2011 Oct; 54(19):6803-11. PubMed ID: 21838328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.
    Thatcher JE; Buttrick B; Shaffer SA; Shimshoni JA; Goodlett DR; Nelson WL; Isoherranen N
    Mol Pharmacol; 2011 Aug; 80(2):228-39. PubMed ID: 21521770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of NADPH-cytochrome P450 reductase on all-trans-retinoic acid efficacy and cytochrome P450 26A1 expression in human myeloid leukaemia HL-60 cells.
    Hu L; Lv JF; Zhuo W; Zhang CM; Zhou HH; Fan L
    J Pharm Pharmacol; 2016 Sep; 68(9):1193-202. PubMed ID: 27366899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.
    Njar VC
    Mini Rev Med Chem; 2002 Jun; 2(3):261-9. PubMed ID: 12370067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.
    Gomaa MS; Bridgens CE; Illingworth NA; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    Bioorg Med Chem; 2012 Jul; 20(14):4201-7. PubMed ID: 22727372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases.
    Foti RS; Diaz P; Douguet D
    J Enzyme Inhib Med Chem; 2016; 31(sup2):148-161. PubMed ID: 27424662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.
    Diaz P; Huang W; Keyari CM; Buttrick B; Price L; Guilloteau N; Tripathy S; Sperandio VG; Fronczek FR; Astruc-Diaz F; Isoherranen N
    J Med Chem; 2016 Mar; 59(6):2579-95. PubMed ID: 26918322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.
    Njar VC; Gediya L; Purushottamachar P; Chopra P; Vasaitis TS; Khandelwal A; Mehta J; Huynh C; Belosay A; Patel J
    Bioorg Med Chem; 2006 Jul; 14(13):4323-40. PubMed ID: 16530416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
    Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
    J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.
    Gomaa MS; Bridgens CE; Aboraia AS; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    J Med Chem; 2011 Apr; 54(8):2778-91. PubMed ID: 21428449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays.
    Yee SW; Jarno L; Gomaa MS; Elford C; Ooi LL; Coogan MP; McClelland R; Nicholson RI; Evans BA; Brancale A; Simons C
    J Med Chem; 2005 Nov; 48(23):7123-31. PubMed ID: 16279770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]-1H-triazoles.
    Pautus S; Yee SW; Jayne M; Coogan MP; Simons C
    Bioorg Med Chem; 2006 Jun; 14(11):3643-53. PubMed ID: 16458519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of substituted imidazole and triazole N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme CYP26.
    Pautus S; Aboraia AS; Bassett CE; Brancale A; Coogan MP; Simons C
    J Enzyme Inhib Med Chem; 2009 Apr; 24(2):487-98. PubMed ID: 18608743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells.
    Gomaa MS; Armstrong JL; Bobillon B; Veal GJ; Brancale A; Redfern CP; Simons C
    Bioorg Med Chem; 2008 Sep; 16(17):8301-13. PubMed ID: 18722776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-(2-Methylfuran-3-carboxamido)-3-phenylpropanoic acid, a potential CYP26A1 inhibitor to enhance all-trans retinoic acid-induced leukemia cell differentiation based on virtual screening and biological evaluation.
    Li F; Zhao D; Ren J; Hao F; Liu G; Jin S; Jing Y; Cheng M
    Bioorg Med Chem; 2013 Jun; 21(11):3256-61. PubMed ID: 23601821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the
    Stevison F; Hogarth C; Tripathy S; Kent T; Isoherranen N
    Drug Metab Dispos; 2017 Jul; 45(7):846-854. PubMed ID: 28446509
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.